NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ENTX

Entera Bio Ltd

Jun 23 • 04:00PM ET

1.96

Dollar change -0.02
Percentage change -1.01	%

Healthcare • Biotechnology • Israel • NASD

Peers: JNJ LLY AMGN BMY PFE SNY VRTX BIIB GSK NBIX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.26	Insider Own	29.60%	Shs Outstand	45.42M	Perf Week	5.38%
Market Cap	89.09M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	32.00M	Perf Month	2.62%
Enterprise Value	68.74M	PEG	-	EPS next Q	-0.11	Inst Own	22.49%	Short Float	0.25%	Perf Quarter	0.51%
Income	-10.09M	P/S	404.96	EPS this Y	-120.00%	Inst Trans	132.37%	Short Ratio	1.91	Perf Half Y	-11.71%
Sales	0.22M	P/B	4.59	EPS next Y	-	ROA	-63.39%	Short Interest	0.08M	Perf YTD	-7.55%
Book/sh	0.43	P/C	4.33	EPS next 5Y	-	ROE	-71.46%	52W High	2.79 -29.75%	Perf Year	-7.11%
Cash/sh	0.45	P/FCF	-	EPS past 3/5Y	18.40% 22.19%	ROIC	-51.94%	52W Low	1.41 39.01%	Perf 3Y	13.29%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-31.82% -5.17%	Gross Margin	4.04%	Volatility	3.82% 4.30%	Perf 5Y	2.08%
Dividend TTM	-	EV/Sales	312.46	EPS Y/Y TTM	9.57%	Oper. Margin	-4522.87%	ATR (14)	0.17	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.07	Sales Y/Y TTM	607.14%	Profit Margin	-4525.11%	RSI (14)	46.91	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	13.07	EPS Q/Q	-7.83%	SMA20	-1.43%	Beta	1.48	Target Price	10.00
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-3.25%	Rel Volume	2.39	Prev Close	1.98
Employees	20	LT Debt/Eq	0.00	Earnings	May 09 AMC	SMA200	-1.89%	Avg Volume	41.41K	Price	1.96
IPO	Jun 28, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	185.71% -	Trades		Volume	96,000	Change	-1.01%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-22-21	Initiated	Aegis Capital	Buy	$12

May-09-25 04:05PM	Entera Bio Announces First Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Apr-15-25 08:30AM	Entera Bio's EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis - Highlighted as Oral Presentation at WCO-IOF ESCEO (GlobeNewswire)
Mar-28-25 04:05PM	Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-18-25 11:37AM	Opko and Entera focus on oral care for obesity and metabolic disorders (Pharmaceutical Technology)
Mar-17-25 08:00AM	OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders (GlobeNewswire)
08:30AM	Loading…
Feb-24-25 08:30AM	Entera Bio to Participate in Upcoming Events (GlobeNewswire)
Feb-19-25 08:00AM	EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (GlobeNewswire)
Jan-27-25 08:00AM	Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Nov-08-24 05:15PM	Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Sep-25-24 08:30AM	Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders (GlobeNewswire)
Sep-18-24 09:40AM	Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-02-24 09:40AM	Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year? (Zacks)
Aug-20-24 08:00AM	Entera Bio to Participate in Upcoming Investor and Scientific Conferences (GlobeNewswire)
Aug-15-24 12:00PM	All You Need to Know About Entera Bio (ENTX) Rating Upgrade to Buy (Zacks)
04:05PM	Loading…
Aug-09-24 04:05PM	Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-01-24 08:30AM	Entera's EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual Meeting - Key SABRE Update Also Expected (GlobeNewswire)
Jul-23-24 06:28AM	3 Meme Stocks to Buy and Hold for Potential 300% Returns in 3 Years (InvestorPlace)
Jul-08-24 03:53PM	3 Meme Stocks That Can Surge by 200% Before 2025 (InvestorPlace) +5.99%
Jul-02-24 05:05PM	3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns (InvestorPlace)
Jun-25-24 04:37PM	3 Meme Stocks to Buy on the Dip: June 2024 (InvestorPlace) -9.22%
Jun-20-24 12:38PM	7 Penny Stocks to Turn $3 Into $1 Million Within 36 Months (InvestorPlace)
06:47AM	Rags to Riches: 3 Penny Stocks That Could Make Early Investors Rich (InvestorPlace)
06:47AM	Rag to Riches: 3 Penny Stocks That Could Make Early Investors Rich (InvestorPlace)
Jun-17-24 01:00PM	3 Penny Stocks to Turn $50,000 Into $1 Million: June 2024 (InvestorPlace)
Jun-10-24 07:22PM	Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024 (InvestorPlace)
Jun-07-24 07:30AM	Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar (InvestorPlace)
Jun-03-24 09:40AM	Has Entera Bio (ENTX) Outpaced Other Medical Stocks This Year? (Zacks)
08:00AM	Entera Bio Reports Phase 1 Clinical Data of First-in-Class, Oral PTH(1-34) Peptide Candidate (EB612) for Patients with Hypoparathyroidism at ENDO 2024 (GlobeNewswire)
May-23-24 06:45AM	The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom (InvestorPlace)
09:40AM	Loading…
May-16-24 09:40AM	Are Medical Stocks Lagging Entera Bio (ENTX) This Year? (Zacks)
May-15-24 08:00AM	Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member (GlobeNewswire)
May-13-24 07:00AM	Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024 (GlobeNewswire)
May-10-24 08:53PM	ENTX Stock Earnings: Entera Bio Beats EPS for Q1 2024 (InvestorPlace)
04:10PM	Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-26-24 06:00PM	Entera Bio Ltd. (ENTX) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
Apr-18-24 06:15PM	Why the Market Dipped But Entera Bio Ltd. (ENTX) Gained Today (Zacks) -11.16%
Apr-15-24 03:43PM	Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024? (InvestorPlace) -15.44%
Apr-12-24 09:40AM	Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year? (Zacks) +12.03%
Apr-09-24 09:09AM	Here's Why You Should Invest in Entera Bio (ENTX) Stock Now (Zacks) +15.38%
Apr-08-24 08:30AM	Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research (GlobeNewswire)
Mar-26-24 08:30AM	Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months (GlobeNewswire)
Mar-24-24 03:54PM	12 Best Biotech Penny Stocks to Invest In (Insider Monkey)
Mar-20-24 08:00AM	Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome (GlobeNewswire) +7.79%
Mar-08-24 04:05PM	Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire) +5.04%
Mar-04-24 08:30AM	Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +19.44%
Jan-30-24 08:30AM	Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-03-24 08:00AM	Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule (GlobeNewswire)
Dec-26-23 08:00AM	Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025 (GlobeNewswire)
Nov-29-23 08:30AM	Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform (GlobeNewswire)
Nov-14-23 07:30AM	Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development (GlobeNewswire)
Nov-09-23 02:30PM	Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis (GlobeNewswire) +20.64%
Oct-16-23 08:00AM	Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting (GlobeNewswire)
Sep-13-23 01:18PM	OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations (Zacks)
Sep-12-23 08:30AM	Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes (GlobeNewswire)
Sep-05-23 08:00AM	Entera Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-16-23 08:30AM	Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting (GlobeNewswire) +5.02%
Aug-11-23 04:05PM	Entera Bio Announces Q2 2023 Financial Results and Corporate Updates (GlobeNewswire) -17.57%
Jun-07-23 07:30AM	Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors (GlobeNewswire)
May-07-23 08:10AM	Entera Bio First Quarter 2023 Earnings: US$0.076 loss per share (vs US$0.13 loss in 1Q 2022) (Simply Wall St.)
May-05-23 05:15PM	Entera Bio Ltd. (ENTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -6.70% +7.30%
04:05PM	Entera Bio Announces Q1 2023 Financial Results and Corporate Updates (GlobeNewswire)
May-04-23 10:00AM	Will Entera Bio Ltd. (ENTX) Report Negative Q1 Earnings? What You Should Know (Zacks)
May-03-23 09:34AM	Enteras Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics (GlobeNewswire) +10.00%
Apr-26-23 08:30AM	Menopause Luminary, Dr. Steven R. Goldstein, Joins Enteras Clinical and Scientific Advisory Board (GlobeNewswire)
Apr-03-23 07:00AM	Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program (GlobeNewswire) -13.36%
Mar-31-23 05:15PM	Entera Bio Ltd. (ENTX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:00PM	Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022 (GlobeNewswire)
Mar-23-23 09:27AM	Entera Bio Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Mar-10-23 08:05AM	Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely? (Simply Wall St.)
Feb-20-23 08:34AM	Entera Bio (ENTX) to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-15-23 10:00AM	Entera Bio Announces FDAs Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis (GlobeNewswire) +10.99%
Feb-13-23 09:00AM	Entera Bio to Participate in the SVB Securities Global Biopharma Conference (GlobeNewswire)
Feb-10-23 06:00PM	Entera Bio Ltd. (ENTX) Outpaces Stock Market Gains: What You Should Know (Zacks)
Feb-02-23 06:00PM	Entera Bio Ltd. (ENTX) Flat As Market Gains: What You Should Know (Zacks)
Jan-27-23 06:00PM	Entera Bio Ltd. (ENTX) Stock Sinks As Market Gains: What You Should Know (Zacks)
Jan-25-23 06:15PM	Entera Bio Ltd. (ENTX) Flat As Market Sinks: What You Should Know (Zacks)
Jan-18-23 06:15PM	Entera Bio Ltd. (ENTX) Gains As Market Dips: What You Should Know (Zacks)
Nov-16-22 07:27AM	New Strong Buy Stocks for November 16th (Zacks) +15.76%
Nov-10-22 05:45PM	Entera Bio Ltd. (ENTX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -19.20%
04:15PM	Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022 (GlobeNewswire)
Oct-06-22 07:00AM	Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis (GlobeNewswire)
Oct-01-22 08:28AM	Is Entera Bio (NASDAQ:ENTX) In A Good Position To Invest In Growth? (Simply Wall St.)
Sep-21-22 08:30AM	Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613s Potential Impact on Wednesday, September 28th @ 10am ET (GlobeNewswire) +6.61%
Sep-12-22 04:30PM	Entera Bio to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
06:30AM	Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting (GlobeNewswire)
Aug-11-22 06:30AM	Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022 (GlobeNewswire)
Jul-26-22 07:30AM	Entera Bio Announces Formation of Clinical and Scientific Advisory Board and Poster Presentation at ASBMR 2022 Annual Meeting (GlobeNewswire) +6.82%
Jul-18-22 09:11AM	Entera Bio Outlines Pivotal Osteoporosis Trial, Names New CEO (Benzinga)
07:05AM	Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position (GlobeNewswire)
Jun-17-22 05:00PM	Entera Bio Announces Departure of Dr. Phillip Schwartz, the Companys President of Research & Development to Pursue Outside Opportunities (GlobeNewswire) -5.99%
May-16-22 08:00AM	Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy (GlobeNewswire) +9.77%
May-12-22 08:00AM	Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
May-05-22 08:00AM	Entera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule Therapeutics (GlobeNewswire)
Apr-28-22 08:00AM	Entera Bio to Report First Quarter 2022 Financial Results on May 12 (GlobeNewswire)
Apr-08-22 05:02PM	Recession Fears are Creating a Golden Opportunity for Biotech Stocks (InvestorPlace)
Mar-22-22 08:00AM	Entera Bio to Present at 2022 Maxim Virtual Growth Conference (GlobeNewswire)
Mar-16-22 06:14AM	Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-08-22 06:30AM	Entera Bio Reports Financial Results for the Year Ended December 31, 2021 (GlobeNewswire)
Mar-03-22 09:50AM	Entera Bio to Report Business and Financial Results for the Year Ended December 31, 2021 on March 8, 2022 (GlobeNewswire)

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH(1-34), GLP-1 and GLP-2. The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LIEBERMAN GERALD M	Director	Apr 01 '25	Option Exercise	1.00	23,952	23,952	300,160	Apr 03 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ENTX

Entera Bio Ltd

Upgrade your FINVIZ experience